Arcus Biosciences Inc
$ 23.33
1.04%
29 Dec - close price
- Market Cap 2,856,892,000 USD
- Current Price $ 23.33
- High / Low $ 23.62 / 22.66
- Stock P/E N/A
- Book Value 4.07
- EPS -3.42
- Next Earning Report 2026-02-25
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.21 %
- ROE -0.68 %
- 52 Week High 26.40
- 52 Week Low 6.50
About
Arcus Biosciences, Inc. (RCUS) is a clinical-stage biopharmaceutical company located in Hayward, California, dedicated to pioneering innovative cancer therapies through its robust immune-oncology and targeted treatment pipeline. With a focus on harnessing the body’s immune system to combat tumors, Arcus employs proprietary technologies and collaborative partnerships to advance its drug candidates through critical clinical stages. As it approaches significant milestones in development and potential regulatory approvals, Arcus presents a compelling investment opportunity for institutional investors looking to capitalize on growth in the rapidly evolving biopharmaceutical sector.
Analyst Target Price
$32.10
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-28 | 2025-08-06 | 2025-05-06 | 2025-02-19 | 2024-11-06 | 2024-08-08 | 2024-05-08 | 2024-02-21 | 2023-11-07 | 2023-08-07 | 2023-05-09 | 2023-02-28 |
| Reported EPS | -1.27 | 0 | -1.14 | -1.03 | -1 | -1.02 | -0.05 | -1.08 | -0.94 | -1.04 | -1.09 | -0.93 |
| Estimated EPS | -1.28 | -1.12 | -0.93 | -1.2031 | -1.06 | -1.1 | -0.95 | -1.02 | -1.13 | -1.1 | -1.16 | -1.07 |
| Surprise | 0.01 | 1.12 | -0.21 | 0.1731 | 0.06 | 0.08 | 0.9 | -0.06 | 0.19 | 0.06 | 0.07 | 0.14 |
| Surprise Percentage | 0.7813% | 100% | -22.5806% | 14.3878% | 5.6604% | 7.2727% | 94.7368% | -5.8824% | 16.8142% | 5.4545% | 6.0345% | 13.0841% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-25 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -1.19 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RCUS
2025-12-23 07:09:38
Arcus Biosciences (RCUS) recently discontinued a Phase 3 gastric cancer trial for domvanalimab, shifting focus to its casdatifan pipeline. Despite this setback, the share price has seen a significant 90-day return, indicating investor optimism about long-term potential. The company's valuation narrative suggests it is undervalued at $23.22 against a fair value of $33.22, contingent on successful casdatifan execution and future trial wins.
2025-12-21 13:09:53
Arcus Biosciences' Co-Founder, Terry Rosen, recently sold US$1.2m worth of shares at US$22.01, representing 2.0% of his holding. While insiders sold more shares than they bought over the last year, insiders still own 3.7% of the company, valued at US$100m. This insider selling, coupled with a lack of recent insider buying, suggests caution despite significant insider ownership.
2025-12-20 14:09:10
Co-founder Terry Rosen recently sold US$1.2m worth of Arcus Biosciences shares, representing 2.0% of his holding. While insider buying has been less than selling over the past year, insiders still own 3.7% of the company, valued at US$100m. This insider selling at current prices prompts caution despite the significant insider ownership.
2025-12-20 13:09:03
An insider at Arcus Biosciences recently sold shares worth US$1.2 million, though this only represented 2.0% of their holding. While there were more insider sales than purchases over the past year, resulting in a net sale of 138.27k shares for US$3.0m versus 39.80k shares bought for US$403k, the fact that the recent sale occurred around the current share price makes analysts cautious rather than overly concerned. Despite the insider selling, Arcus Biosciences has significant insider ownership of 3.7%, valued at approximately US$100 million.
2025-12-20 10:08:54
Squarepoint Ops LLC significantly increased its stake in Arcus Biosciences, Inc. by 163.7% in Q2, contributing to high institutional ownership of 92.89%. Despite this, significant insider selling, including by the CEO, totaling $9.24 million in the last 90 days, could negatively impact short-term sentiment. Analysts maintain a "Moderate Buy" consensus with an average price target of $28.89, while RCUS trades around $21.99 and remains unprofitable.
2025-12-19 14:08:55
Arcus Biosciences (NYSE: RCUS), a clinical-stage biopharmaceutical company focused on cancer, inflammatory, and autoimmune diseases, announced that its CEO, Terry Rosen, Ph.D., will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 3:00 pm PT. A live webcast and replay of the presentation will be available on the company's website. Arcus Biosciences is advancing multiple investigational medicines into clinical trials, including casdatifan for clear cell renal cell carcinoma and quemliclustat for pancreatic cancer.
